U.S. markets closed

Standard BioTools Inc. (LAB)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
2.4000-0.0100 (-0.41%)
Al cierre: 04:00PM EDT
2.3400 -0.06 (-2.50%)
Fuera de horario: 06:40PM EDT

Standard BioTools Inc.

2 Tower Place
Suite 2000
South San Francisco, CA 94080
United States
650 266 6000
https://www.standardbio.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo534

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Michael Egholm Ph.D.President, CEO & Director1.37MN/D1963
Mr. Jeffrey G. BlackChief Financial Officer687.06kN/D1969
Mr. Hanjoon KimChief Operating Officer723kN/D1971
Dr. Shane Bowen Ph.D.Chief Technology OfficerN/DN/DN/D
David HolmesInvestor RelationsN/DN/DN/D
Mr. Adam TaichChief Strategy OfficerN/DN/D1976
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Standard BioTools Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 4; Junta: 8; Derechos del accionista: 9; Compensación: 10.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.